生物药在肿瘤治疗领域的临床研究进展  

Development of therapeutic biologics in cancer treatment

作　　者：张锴婷 陈乃涵 ZHANG Kaiting;CHEN Naihan(Pfizer(China)Research and Development Co.,Ltd,Beijing 100010,China)

机构地区：[1]辉瑞(中国)研究开发有限公司

出　　处：《中国临床药理学与治疗学》2020年第1期32-43,共12页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：肿瘤治疗一直是药物研发的热点领域,而生物药在其中扮演了重要的角色。本文对生物药在肿瘤治疗领域的临床进展进行了综述,根据机制,将生物药分为靶向治疗和免疫治疗两大类,靶向治疗主要从单克隆抗体和抗体偶联药物两个方面展开,免疫治疗重点介绍检查点抑制剂和双特异性抗体。Cancer treatment is always the focus of pharmaceutical development while therapeutic biologics play an important role alongside. This review is focused on the development of therapeutic biologics in cancer treatment and categorized by targeted therapy and immunotherapy by mechanism. In targeted therapy, monoclonal antibodies, biosimilars and antibody-drug conjugates are discussed in details, while for immunotherapy, checkpoint inhibitors, T-cell transfer therapy and bispecific antibody are introduced, respectively.

关 键 词：生物药 肿瘤治疗 靶向治疗 免疫治疗 

分 类 号：R73[医药卫生—肿瘤]